Company Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease.
The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease.
It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering.
uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 1998 |
| IPO Date | Jun 20, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 209 |
| CEO | Matthew Kapusta |
Contact Details
Address: Paasheuvelweg 25 Amsterdam, 1105 BP Netherlands | |
| Phone | 31 20 240 6000 |
| Website | uniqure.com |
Stock Details
| Ticker Symbol | QURE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590560 |
| CUSIP Number | N90064101 |
| ISIN Number | NL0010696654 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Craig Kapusta CPA | Chief Executive Officer and Executive Director |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site |
| Richard Porter Ph.D. | Chief Business and Scientific Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Erin Boyer | Chief People and Culture Officer |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Eileen Sawyer | Vice President of Global Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 16, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 8, 2025 | 8-K | Current Report |
| Jan 8, 2025 | 424B5 | Filing |
| Jan 7, 2025 | 424B5 | Filing |
| Jan 7, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Dec 17, 2024 | SCHEDULE 13G | Filing |